Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 501–600 of 1,015
Hsu, C., Lee, H.-C., & Wei, Y.-H. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i47.8880 · Cited by 114
Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment
Sun, H.-R., Wang, S., Yan, S.-C., Zhang, Y., Nelson, P. J., Jia, H.-L., Qin, L.-X., & Dong, Q.-Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01104 · Cited by 103
van Gils, N., Denkers, F., & Smit, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659253 · Cited by 113
Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives
Jing, Z., Du, Q., Zhang, X., & Zhang, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137147 · Cited by 112
Carbon quantum dots: A promising nanocarrier for bioimaging and drug delivery in cancer
Jana, P., & Dev, A. (2022) · Materials Today Communications · doi:10.1016/j.mtcomm.2022.104068 · Cited by 125
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 128
Normalizing Tumor Microenvironment Based on Photosynthetic Abiotic/Biotic Nanoparticles
Zheng, D., Li, B., Xu, L., Zhang, Q.-L., Fan, J.-X., Li, C.-X., & Zhang, X.-Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b02977 · Cited by 103
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 108
Luo, T., Wang, D., Liu, L., Zhang, Y., Han, C., Xie, Y., Liu, Y., Liang, J., Qiu, G., Li, H., et al. (2021) · Advanced Science · doi:10.1002/advs.202101065 · Cited by 106
Stephenson, M., Reichardt, C. L., Pinto, M., Wächtler, M., Sainuddin, T., Shi, G., Yin, H., Monro, S. M. A., Sampson, E., Dietzek, B., et al. (2014) · The Journal of Physical Chemistry A · doi:10.1021/jp504330s · Cited by 108
Targeting DNA Replication Stress for Cancer Therapy
Zhang, J., Dai, Q., Park, D., & Deng, X. (2016) · Genes · doi:10.3390/genes7080051 · Cited by 102
“In addition, cancer cells typically have higher levels of ROS due to increased MYC activity [8], enhanced production by mitochondria [9], or hypoxia owing to relatively insufficient vascularization [10].”
BackgroundMitra, K., Lyons, C. E., & Hartman, M. C. T. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201806911 · Cited by 102
Autophagy: Detection, regulation and its role in cancer and therapy response
Hönscheid, P., Datta, K., & Muders, M. H. (2014) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.907932 · Cited by 104
Ferroquine, the next generation antimalarial drug, has antitumor activity
Kondratskyi, A., Kondratska, K., Abeele, F. V., Gordienko, D. V., Dubois, C., Toillon, R., Slomianny, C., Lemière, S., Delcourt, P., Dewailly, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16154-2 · Cited by 114
Wang, Y., Liu, Y., Wu, H., Zhang, J., Tian, Q., & Yang, S. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201805764 · Cited by 101
Photodynamic Therapy and the Biophysics of the Tumor Microenvironment
Sorrin, A. J., Ruhi, M. K., Ferlic, N. A., Karimnia, V., Polacheck, W. J., Celli, J. P., Huang, H., & Rizvi, I. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13209 · Cited by 109
Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor
Kumar, R., Kim, E. J., Han, J., Lee, H., Shin, W. S., Kim, H. M., Bhuniya, S., Kim, J. S., & Hong, K. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.010 · Cited by 103
Zhang, L., Lou, J., Lü, M., Gao, C., Zhao, S., Li, B., Liang, S., Li, Y., Li, D., & Liu, M. (2015) · The EMBO Journal · doi:10.15252/embj.201591803 · Cited by 105
Pang, L., Zhang, C., Qin, J., Han, L., Li, R., Hong, C., He, H., & Wang, J. (2017) · Drug Delivery · doi:10.1080/10717544.2016.1230903 · Cited by 107
Burke, C. S., Byrne, A., & Keyes, T. E. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b02711 · Cited by 100
Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications
Zhang, Y., Zhang, H., Wang, M., Schmid, T., Xin, Z., Kozhuharova, L., Yu, W.-K., Huang, Y., Cai, F., & Biskup, E. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.652266 · Cited by 114
Li, J., Xia, Y., Sun, B., Zheng, N., Li, Y., Pang, X., Yang, F., Zhao, X., Ji, Z., Yu, H., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01112-5 · Cited by 122
TRAF6 Upregulates Expression of HIF-1α and Promotes Tumor Angiogenesis
Sun, H., Li, X., Meng, Y. J., Li, F., Li, M., & Fang, J. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0370 · Cited by 105
Selective cancer treatment via photodynamic sensitization of hypoxia-responsive drug delivery
He, H., Zhu, R., Sun, W., Cai, K., Chen, Y., & Yin, L. (2017) · Nanoscale · doi:10.1039/c7nr07677k · Cited by 100
Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Li, X., Shepard, H. M., Cowell, J. A., Zhao, C., Osgood, R. J., Rosengren, S., Blouw, B., Garrovillo, S. A., Pagel, M. D., Whatcott, C. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3284 · Cited by 99
Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer
Shah, V. M., Sheppard, B. C., Sears, R. C., & Alani, A. W. G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.041 · Cited by 119
Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth
Miller, K. D., Pniewski, K., Perry, C. E., Papp, S. B., Shaffer, J. D., Velasco-Silva, J. N., Casciano, J. C., Aramburu, T. M., Srikanth, Y. V. V., Cassel, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1847 · Cited by 98
Ding, F., Feng, J. C., Zhang, X., Sun, J., Fan, C., & Ge, Z. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.008 · Cited by 103
Ribatti, D., Solimando, A. G., & Pezzella, F. (2021) · Cancers · doi:10.3390/cancers13143433 · Cited by 111
Unboxing the molecular modalities of mutagens in cancer
Kumari, S., Sharma, S., Advani, D., Khosla, A., Kumar, P., & Ambasta, R. K. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16726-w · Cited by 123
A Nanozyme with Photo‐Enhanced Dual Enzyme‐Like Activities for Deep Pancreatic Cancer Therapy
Li, S., Shang, L., Xu, B., Wang, S., Gu, K. X., Wu, Q., Sun, Y., Zhang, Q., Yang, H., Zhang, F., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201904751 · Cited by 100
Huynh, D. L., Sharma, N., Singh, A. K., Sodhi, S. S., Zhang, J., Mongre, R. K., Ghosh, M., Kim, N., Park, Y. H., & Jeong, D. K. (2017) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(17)30005-5 · Cited by 111
Dual Targeting of Hypoxic and Acidic Tumor Environments with a Cobalt(III) Chaperone Complex
Yamamoto, N., Renfrew, A. K., Kim, B. J., Bryce, N. S., & Hambley, T. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3014713 · Cited by 101
Wang, J., Fang, L., Li, P., Ma, L., Na, W., Cheng, C., Gu, Y., & Deng, D. (2019) · Nano-Micro Letters · doi:10.1007/s40820-019-0305-x · Cited by 101
Metal-organic frameworks for therapeutic gas delivery
Zhou, Y., Yang, T., Liang, K., & Chandrawati, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.005 · Cited by 104
Zhuang, F., Ma, Q., Dong, C., Xiang, H., Shen, Y., Sun, P., Li, C., Chen, Y., Lu, B., Chen, Y., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c09505 · Cited by 100
Molecular mechanisms of mTOR regulation by stress
Heberle, A. M., Prentzell, M. T., van Eunen, K., Bakker, B. M., Grellscheid, S. N., & Thedieck, K. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.970489 · Cited by 97
Kumar, S., & Mehta, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049321 · Cited by 101
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Xu, J., Pham, C. G., Albanese, S. K., Dong, Y., Oyama, T., Lee, C.-H., Rodrik-Outmezguine, V., Yao, Z., Han, S., Chen, D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86120 · Cited by 97
Zeng, Z., Xu, F., Zheng, H., Chen, P., Chen, Q., Zeng, Y., Zhong, J., Deng, S.-J., Liu, M., Huang, K., et al. (2019) · Theranostics · doi:10.7150/thno.34559 · Cited by 99
Peng, C., Huang, Y., & Zheng, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.020 · Cited by 102
Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer
Agnihotri, N., Kumar, S., & Mehta, K. (2013) · Breast Cancer Research · doi:10.1186/bcr3371 · Cited by 108
Hypoxia-activated prodrugs and redox-responsive nanocarriers
Zeng, Y., Ma, J., Zhan, Y., Xu, X., Zeng, Q., Liang, J., & Chen, X. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s173431 · Cited by 106
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 104
Zhao, X., Dai, Y., Ma, F., Misal, S., Hasrat, K., Zhu, H., & Qi, Z. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.128133 · Cited by 97
Recent advances in redox-responsive nanoparticles for combined cancer therapy
Yang, Y., & Sun, W. C. (2022) · Nanoscale Advances · doi:10.1039/d2na00222a · Cited by 104
Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine
Wang, Q., Atluri, K., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceuticals · doi:10.3390/ph16030433 · Cited by 113
Disruption of cytochrome c oxidase function induces the Warburg effect and metabolic reprogramming
Srinivasan, S., Guha, M., Dong, D. W., Whelan, K. A., Ruthel, G. T., Uchikado, Y., Natsugoe, S., Nakagawa, H., & Avadhani, N. G. (2015) · Oncogene · doi:10.1038/onc.2015.227 · Cited by 111
The impact of hypoxia in pancreatic cancer invasion and metastasis
Díaz, B., & Yuen, A. (2014) · Hypoxia · doi:10.2147/hp.s52636 · Cited by 116
Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., Zhan, J.-H., Zeng, K.-M., Huang, Y., Zhao, H.-Y., & Zhang, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.027 · Cited by 95
Thambi, T., Son, S., Lee, D. S., & Park, J. H. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.10.011 · Cited by 95
Sanada, F., Kim, J., Czarna, A., Chan, N. Y., Signore, S., Ogórek, B., Isobe, K., Wybieralska, E., Borghetti, G., Pesapane, A., et al. (2013) · Circulation Research · doi:10.1161/circresaha.114.302500 · Cited by 99
Janus-Faced Tumor Microenvironment and Redox
Khramtsov, V. V., & Gillies, R. J. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5864 · Cited by 100
Sun, Y., Sun, P., Li, Z., Qu, L., & Guo, W. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00179a · Cited by 98
Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier
Hersh, A. M., Bhimreddy, M., Weber-Levine, C., Jiang, K., Alomari, S., Theodore, N., Manbachi, A., & Tyler, B. (2022) · Cancers · doi:10.3390/cancers14194920 · Cited by 98
Exploiting Copper Redox for 19F Magnetic Resonance-Based Detection of Cellular Hypoxia
Xie, D., King, T. L., Banerjee, A., Kohli, V., & Que, E. L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b13215 · Cited by 96
Imaging Tumor Hypoxia to Advance Radiation Oncology
Lee, C.-T., Boss, M., & Dewhirst, M. W. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5759 · Cited by 107
Kheshtchin, N., Arab, S., Ajami, M., Mirzaei, R., Ashourpour, M., Mousavi-Niri, N., Khosravianfar, N., Jadidi‐Niaragh, F., Namdar, A., Noorbakhsh, F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1879-5 · Cited by 96
Batushansky, A., Toubiana, D., & Fait, A. (2016) · BioMed Research International · doi:10.1155/2016/8313272 · Cited by 111
Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy
Liu, H., Zhang, Y., Xie, Y., Cai, Y., Baiyang, L., Li, W. J., Zeng, L.-Y., Li, Y., & Yu, R. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s125286 · Cited by 94
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
Solimando, A. G., Summa, S. D., Vacca, A., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12113380 · Cited by 98
Murata, K., Fang, C., Terao, C., Γιαννοπούλου, Ε., Lee, Y. J., Lee, M. J., Mun, S. H., Bae, S., Qiao, Y., Yuan, R., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.018 · Cited by 101
Rami, M., Dubois, L. J., Parvathaneni, N.-K., Alterio, V., van Kuijk, S. J. A., Monti, S. M., Lambin, P., Simone, G. D., Supuran, C. T., & Winum, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4009532 · Cited by 93
Mechanisms of Plasma Medicine: Coupling Plasma Physics, Biochemistry, and Biology
Graves, D. B. (2017) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2017.2710880 · Cited by 103
Wang, H., Zhu, W., Feng, L., Chen, Q., Chao, Y., Dong, Z., & Liu, Z. (2017) · Nano Research · doi:10.1007/s12274-017-1858-y · Cited by 95
Tang, Q., Cheng, Z., Yang, N., Li, Q., Wang, P., Chen, D., Wang, W., Song, X., & Dong, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.005 · Cited by 94
Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
Montemagno, C., & Pagès, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00584 · Cited by 104
Thionated organic compounds as emerging heavy-atom-free photodynamic therapy agents
Ortiz‐Rodríguez, L. A., & Crespo‐Hernández, C. E. (2020) · Chemical Science · doi:10.1039/d0sc04747c · Cited by 97
Jiang, Q., Liu, L., Li, Q., Cao, Y., Chen, D., Du, Q.-S., Yang, X., Huang, D., Pei, R., Chen, X., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00811-w · Cited by 99
Hypoxia-Activated PEGylated Paclitaxel Prodrug Nanoparticles for Potentiated Chemotherapy
Hao, D., Meng, Q., Jiang, B., Lu, S., Xiang, X., Pei, Q., Yu, H., Jing, X., & Xie, Z. (2022) · ACS Nano · doi:10.1021/acsnano.2c05341 · Cited by 97
Smart Nanozymes for Cancer Therapy: The Next Frontier in Oncology
Navya, P. N., Mehla, S., Begum, A., Chaturvedi, H. K., Ojha, R., Hartinger, C. G., Plebanski, M., & Bhargava, S. K. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300768 · Cited by 115
Wei, Z., Shan, Y., Li, T., Liu, Y., Zhu, Z., Liu, Z., Wu, Y., Chen, W., Wang, A., & Lu, Y. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22686 · Cited by 101
Feng, Z., Tao, P., Zou, L., Gao, P., Liu, Y., Liu, X., Wang, H., Liu, S., Dong, Q., Li, J., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b09721 · Cited by 93
Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX
Lau, J., Lin, K., & Bénard, F. (2017) · Theranostics · doi:10.7150/thno.21848 · Cited by 100
Zhang, Y., Wang, B., Zhao, R., Zhang, Q., & Kong, X. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111099 · Cited by 96
Nagpal, N., Ahmad, H. M., Chameettachal, S., Sundar, D., Ghosh, S., & Kulshreshtha, R. (2015) · Scientific Reports · doi:10.1038/srep09650 · Cited by 92
Sun, X., Dong, X., Lin, L., Jiang, X. L., Wei, Z., Zhai, B., Sun, B., Zhang, Q., Wang, X., Jiang, H., et al. (2013) · FEBS Journal · doi:10.1111/febs.12577 · Cited by 92
An Insertion/Deletion Polymorphism within RERT-lncRNA Modulates Hepatocellular Carcinoma Risk
Zhu, Z., Gao, X., He, Y., Zhao, H., Yu, Q., Jiang, D., Zhang, P., Ma, X., Huang, H., Dong, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0010 · Cited by 94
Peela, N., Truong, D., Saini, H., Chu, H., Mashaghi, S., Ham, S. L., Singh, S., Tavana, H., Mosadegh, B., & Nikkhah, M. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.017 · Cited by 91
Sistigu, A., Modugno, F. D., Manic, G., & Nisticò, P. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.05.008 · Cited by 111
Qi, Y., Guo, L., Chen, L.-L., Li, H., Yang, Y., Jiang, A.-Q., & Zhu, H. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213460 · Cited by 93
Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia
Bonnin, D. A. A., Havrda, M. C., Lee, M. C., Liu, H., Zhang, Z., Nguyen, L., Harrington, L. X., Hassanpour, S., Cheng, C., & Israel, M. A. (2017) · Oncogene · doi:10.1038/onc.2017.404 · Cited by 98
Addressing intra-tumoral heterogeneity and therapy resistance
Rybinski, B., & Yun, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11875 · Cited by 107
Kirsch, D. G., Diehn, M., Kesarwala, A. H., Maity, A. M., Morgan, M. A., Schwarz, J. K., Bristow, R. G., Demaria, S., Eke, I., Griffin, R. J., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx231 · Cited by 102
Oncostatin M: A mysterious cytokine in cancers
Masjedi, A., Hajizadeh, F., Dargani, F. B., Beyzai, B., Aksoun, M., Hojjat‐Farsangi, M., Zekiy, A. O., & Jadidi‐Niaragh, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107158 · Cited by 91
Wulbrand, C., Seidl, C., Gaertner, F. C., Bruchertseifer, F., Morgenstern, A., Essler, M., & Senekowitsch–Schmidtke, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064730 · Cited by 100
Zhang, M., Ye, J.-J., Xia, Y., Wang, Z.-Y., Li, C.-X., Wang, X.-S., Yu, W., Song, W., Feng, J., & Zhang, X.-Z. (2019) · ACS Nano · doi:10.1021/acsnano.9b07330 · Cited by 89
Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02724-y · Cited by 89
Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response
Huang, X., & Zuo, J. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt141 · Cited by 97
Wu, X., Zhu, Y., Huang, W., Li, J., Zhang, B., Li, Z., & Yang, X. (2018) · Advanced Science · doi:10.1002/advs.201700859 · Cited by 89
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 96
Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats
Staedtke, V., Bai, R.-Y., Sun, W., Huang, J., Kibler, K. K., Tyler, B. M., Gallia, G. L., Kinzler, K., Vogelstein, B., Zhou, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3627 · Cited by 89
Kuonen, F., Secondini, C., & Rüegg, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1758 · Cited by 92
Ma, L., Li, G., Zhu, H., Dong, X., Zhao, D., Jiang, X. L., Li, J., Qiao, H., Ni, S., & Sun, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.011 · Cited by 91
The SIAH2-NRF1 axis spatially regulates tumor microenvironment remodeling for tumor progression
Ma, B., Cheng, H., Mu, C., Geng, G., Zhao, T., Luo, Q., Ma, K., Chang, R., Liu, Q., Gao, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08618-y · Cited by 89
van Elmpt, W., Zegers, C. M. L., Reymen, B. J. T., Even, A. J. G., Dingemans, A. C., Öllers, M., Wildberger, J. E., Mottaghy, F. M., Das, M., Troost, E. G. C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3169-4 · Cited by 94
Hypoxia increases genome-wide bivalent epigenetic marking by specific gain of H3K27me3
Prickaerts, P., Adriaens, M. E., Beucken, T. V. D., Koch, E., Dubois, L., Dahlmans, V. E. H., Gits, C., Evelo, C. T. A., Chan-Seng-Yue, M., Wouters, B. G., et al. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0086-0 · Cited by 87
Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer
Tran, T. Q., Lowman, X. H., & Kong, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2506 · Cited by 103
Cancer cell adaptation to hypoxia involves a HIF‐GPRC5A‐YAP axis
Greenhough, A., Bagley, C., Heesom, K. J., Gurevich, D. B., Gay, D., Bond, M., Collard, T. J., Paraskeva, C., Martin, P., Sansom, O. J., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708699 · Cited by 87
Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy
He, M., Yang, T., Wang, Y., Wang, M., Chen, X., Ding, D., Zheng, Y., & Chen, H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002104 · Cited by 96
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.